NASDAQ:ODT - Odonate Therapeutics Stock Price, Price Target & More

Odonate Therapeutics trades on the NASDAQ under the ticker symbol "ODT."

Odonate Therapeutics Inc (NASDAQ:ODT) released its quarterly earnings data on Thursday, May, 3rd. The company reported ($0.69) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.85) by $0.16. View Odonate Therapeutics' Earnings History.

3 brokers have issued 12-month price objectives for Odonate Therapeutics' shares. Their predictions range from $27.00 to $40.00. On average, they expect Odonate Therapeutics' stock price to reach $33.50 in the next year. This suggests a possible upside of 40.9% from the stock's current price. View Analyst Ratings for Odonate Therapeutics.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Odonate Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to Odonate Therapeutics include Clovis Oncology (CLVS), Endo International (ENDP), TESARO (TSRO), Spectrum Pharmaceuticals (SPPI), Akcea Therapeutics (AKCA), Enanta Pharmaceuticals (ENTA), Xencor (XNCR), Akorn (AKRX), ACADIA Pharmaceuticals (ACAD), Arena Pharmaceuticals (ARNA), Zogenix (ZGNX), Global Blood Therapeutics (GBT), Puma Biotechnology (PBYI), Myokardia (MYOK) and Prestige Brands (PBH).

(ODT) raised $150 million in an initial public offering (IPO) on Thursday, December 7th 2017. The company issued 5,900,000 shares at a price of $24.00-$27.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and Cowen was co-manager.

Odonate Therapeutics' lock-up period expired on Tuesday, June 5th. Odonate Therapeutics had issued 6,250,000 shares in its initial public offering on December 7th. The total size of the offering was $150,000,000 based on an initial share price of $24.00. Shares of the company owned by company insiders and major shareholders are now eligible to be traded as a result of the expiration of the lock-up period.

News coverage about ODT stock has been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Odonate Therapeutics earned a daily sentiment score of 0.17 on Accern's scale. They also assigned media stories about the company an impact score of 45.84 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

Shares of ODT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of ODT stock can currently be purchased for approximately $23.77.

Odonate Therapeutics has a market capitalization of $643.97 million. The company earns $-32,740,000.00 in net income (profit) each year or ($2.31) on an earnings per share basis. Odonate Therapeutics employs 60 workers across the globe.

Odonate Therapeutics' mailing address is 4747 EXECUTIVE DRIVE SUITE 510, SAN DIEGO CA, 92121. The company can be reached via phone at 858-731-8180 or via email at [email protected]